Daily Bio News Summary — 2026-08-05: Q2 earnings, an Amgen obesity pivot and a CNS mega-merger

Today’s harvest spans 26 articles across six sources — BioSpace, Fierce Biotech, Fierce Pharma, STAT News, MedCity News and the PR Newswire FDA feed — published between August 1 and August 5, 2026. The dominant cluster is second-quarter earnings season: three of the five largest headlines concern big-pharma results or the strategy shifts they set off. Around that core, the batch holds a CNS-focused merger, an OTC regulatory first, a pair of biotech financings, an AI-in-clinical-trials partnership and two notable layoff stories.

Big pharma earnings: Lilly beats, Novo regroups, Gilead diversifies

Eli Lilly delivered what BioSpace frames as a “massive earnings beat”: $23 billion in second-quarter revenue, up 48% year over year, with shares rising nearly 5%. The one caveat in the headline is competitive — Lilly’s oral GLP-1 candidate Foundayo “lags Novo’s rival oral GLP-1” (BioSpace, 2026-08-05).

Novo Nordisk, meanwhile, is in regrouping mode. BioSpace reports that CEO Maziar Mike Doustdar “sees innovation as a matter of survival amid pipeline setbacks,” with the company “focused on building out its pipeline to move past recent clinical roadblocks” — the same thread Fierce Biotech pulled earlier in the week when it reported the CEO “accepts ‘couple of setbacks,’ hunts for bolt-on deals” (that version was skipped as a duplicate of the BioSpace piece).

Gilead is working to diversify beyond HIV: the back half of 2026 is “particularly packed” for its inflammation portfolio, per BioSpace, which frames upcoming inflammation and cancer catalysts as central to the company’s effort to broaden its base.

Amgen rounds out the earnings-adjacent story with a portfolio decision: it has discontinued an early-stage obesity candidate, leaving MariTide as its lead obesity asset, while analysts “seek more M&A” (BioSpace, 2026-08-05). Fierce Pharma separately notes Amgen expects Repatha’s sales momentum to continue.

M&A: a CNS merger and a busy deals tape

The biggest deal headline of the batch: Supernus Pharmaceuticals and Indivior will merge to form a new CNS-focused pharma company (MedCity News, 2026-08-01). That story anchors the week’s M&A theme, which also includes Fierce Biotech’s report that Expedition Therapeutics — backed by Sanofi — landed $115 million to advance its oral DPP1 inhibitor EXPD-101 into a global Phase 2 COPD trial, and BioSpace’s roundup of four potential biotech M&A targets “plus a pretty sure bet from J&J” (2026-08-05). Pfizer’s cost discipline is also deal-relevant: the company added $2.5 billion in planned savings through 2029 (Fierce Pharma, 2026-08-04).

FDA and regulatory news

The PR Newswire FDA feed contributed four items. The most consumer-visible is Reckitt’s announcement that the FDA approved Mucinex 12HR Cold & Fever Multi-Symptom — the first OTC innovation in the cold-and-flu category in 14 years and the company’s first new drug approval (2026-08-05). UCB reported that Epilepsia Open published a post hoc analysis of FINTEPLA (fenfluramine) in Lennox-Gastaut syndrome patients, showing sustained improvements (2026-08-05). On the litigation side, the Federal Circuit affirmed that Aveva Drug Delivery Systems’ generic ZTlido product does not infringe Scilex’s patents, clearing the way for a launch with 180-day exclusivity (2026-08-05). And NIPRO began introducing its ELISIO-HX expanded-hemodialysis dialyzer to U.S. providers following FDA 510(k) clearance (2026-08-04).

Biotech financings and the public markets

Two financings stand out. Expedition Therapeutics’ $115 million raise (above) funds a Phase 2 COPD trial. Attovia Therapeutics aims to raise $289 million in an IPO to advance three immunology and inflammation drugs, including a challenge to Dupixent (Fierce Biotech, 2026-08-05). BioSpace’s NextGen list adds context: five NextGen honorees have gone public this year, and most are hiring (2026-08-05).

AI in drug development

AI continues to migrate into the clinical development workflow. Fierce Biotech reports that CRO Icon has partnered with Anthropic to deploy Claude into clinical trials (2026-08-04). MedCity News covers two AI-native companies: QuantHealth raised $45 million to simulate clinical trials before patients enroll (2026-08-01), and Pathos picked up two cancer drugs poised for clinical development using AI agents (2026-08-01).

Workforce stories

The layoff cluster is notable for its breadth: Lisata Therapeutics is cutting 72% of staff and suing Kuva after their proposed merger fell apart (Fierce Biotech, 2026-08-04), and Jennifer Doudna’s Aurora Therapeutics is abandoning its lead PKU gene-editing program and cutting “several” employees seven months after launching with $16 million in seed financing (BioSpace, 2026-08-05). On the retention side, a BioSpace poll finds over a third of biopharma professionals stay in their jobs for health insurance (2026-08-05).

What this batch is NOT telling us

Absent today: no major AI-bio mega-deal (the Icon-Anthropic tie-up is the closest), no IPO pricing beyond Attovia’s announced intent, no clinical readout with headline-grade data, and no large-scale M&A completion — the Supernus-Indivior merger is announced, not closed. The batch also contains no standalone CRISPR/gene-therapy approvals; the Aurora story is a pivot, not a regulatory event. STAT’s BioNTech CEO transition (Guido Oelkers replacing Ugur Sahin) is the only leadership-change item.

Reading order

For limited time, start with the three earnings pieces (Lilly, Novo, Gilead), then the Amgen obesity decision — together they sketch the capital-allocation mood of big pharma this week. Follow with the Supernus-Indivior merger and Expedition’s $115M round for the deal flow, and finish with the Lisata and Aurora layoffs for the cautionary tail.

How to read the underlying articles

Each item in the numbered list below corresponds to a markdown file in src/content/news/, where the frontmatter’s sourceUrl points at the original article and sourceName identifies the outlet. The frontmatter description fields are the source of every claim in this summary.

Today’s full list

1. MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them — STAT News, 2026-08-05
2. Epilepsia Open publishes results of post hoc data analysis of FINTEPLA (fenfluramine) in patients with Lennox-Gastaut syndrome — PR Newswire FDA, 2026-08-05
3. Reckitt announces U.S. FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first OTC innovation in the cold & flu category in 14 years — PR Newswire FDA, 2026-08-05
4. Aveva Drug Delivery Systems prevails on appeal, Federal Circuit affirms non-infringement of ZTlido patents — PR Newswire FDA, 2026-08-05
5. Lilly drops another gene therapy trial from $1B Prevail buyout — Fierce Biotech, 2026-08-05
6. Sanofi-backed Expedition lands $115M for ph. 2 COPD trial — Fierce Biotech, 2026-08-05
7. Attovia’s CEO aims to scratch itch opportunity with $289M IPO — Fierce Biotech, 2026-08-05
8. Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 — BioSpace, 2026-08-05
9. Novo CEO sees innovation as a matter of survival amid pipeline setbacks — BioSpace, 2026-08-05
10. Bespoke gene-editing outfit abandons lead program, cuts ‘several’ employees — BioSpace, 2026-08-05
11. Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts — BioSpace, 2026-08-05
12. Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A — BioSpace, 2026-08-05
13. 4 potential biotech M&A targets, plus a pretty sure bet from J&J — BioSpace, 2026-08-05
14. Over 1/3 stay in biopharma jobs for health insurance, poll finds — BioSpace, 2026-08-05
15. 5 NextGen winners who went public this year (and which ones are hiring) — BioSpace, 2026-08-05
16. NIPRO launches expanded hemodialysis with ELISIO-HX to U.S. providers following FDA clearance — PR Newswire FDA, 2026-08-04
17. Amgen doesn’t think Repatha’s sales wins will stop anytime soon — Fierce Pharma, 2026-08-04
18. More reductions for Pfizer as it tacks on $2.5B in cost savings — Fierce Pharma, 2026-08-04
19. Icon inks Anthropic deal to deploy Claude into clinical trials — Fierce Biotech, 2026-08-04
20. Lisata lays off 72% of staffers, sues Kuva after merger folds — Fierce Biotech, 2026-08-04
21. BioNTech names Guido Oelkers its new CEO — STAT News, 2026-08-03
22. New study offers additional evidence for the VASCADE MVP XL system’s effectiveness in electrophysiology procedures with large bore sheaths — PR Newswire FDA, 2026-08-03
23. QuantHealth Snags $45M to Simulate Clinical Trials Before Patients Ever Enroll — MedCity News, 2026-08-01
24. Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents — MedCity News, 2026-08-01
25. HHS Is Reviving Its 340B Rebate Push — And Providers Are None Too Pleased — MedCity News, 2026-08-01
26. Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company — MedCity News, 2026-08-01